(Q79443198)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

title

Resistance to gefitinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1

Hidetaka Uramoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

5

Takeshi Hanagiri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Kenji Sugio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Tsunehiro Oyama

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Masakazu Sugaya

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Kosei Yasumoto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

25 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

487-491

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese

23 December 2019

cites work

1 reference

12 December 2020

Genetic testing for chemotherapy in non-small cell lung cancer

1 reference

12 December 2020

The EGF receptor family as targets for cancer therapy

1 reference

12 December 2020

ErbB-targeted therapeutic approaches in human cancer

1 reference

12 December 2020

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

12 December 2020

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

1 reference

12 December 2020

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

Expression of constitutively activated EGFRvIII in non-small cell lung cancer

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

1 reference

12 December 2020

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

12 December 2020

Cancer burden in the year 2000. The global picture

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

12 December 2020

EGFR mutation and response of lung cancer to gefitinib

1 reference

12 December 2020

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

12 December 2020

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

12 December 2020

10.1007/S10147-006-0609-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180521%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference